Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation through the acetylation of cyclooxygenase II. These aspirin-triggered lipoxins (ATL) may mediate some of ASA's beneficial actions and therefore are of interest in the search for novel antiinf lammatories that could manifest fewer unwanted side effects. Here, we report that design modifications to native ATL structure prolong its biostability in vivo. In mouse whole blood, ATL analogs protected at carbon 15 [15(R͞S)-methyllipoxin A 4 (ATLa 1 )] and the omega end [15-epi-16-(paraf luoro)-phenoxy-LXA 4 (ATLa 2 )] were recoverable to Ϸ90 and 100% at 3 hr, respectively, compared with a Ϸ40% loss of native lipoxin A 4 . ATLa 2 retains bioactivity and, at levels as low as Ϸ24 nmol͞mouse, potently inhibited tumor necrosis factor-␣-induced leukocyte recruitment into the dorsal air pouch. Inhibition was evident by either local intra-air pouch delivery (Ϸ77% inhibition) or systemic delivery by intravenous injection (Ϸ85% inhibition) and proved more potent than local delivery of ASA. Rank order for inhibiting polymorphonuclear leukocyte infiltration was: ATLa 2 (10 g, i.v.) ϷATLa 2 (10 g, local) Ϸdexamethasone (10 g, local) >ASA (1.0 mg, local). Applied topically to mouse ear skin, ATLa 2 also inhibited polymorphonuclear leukocyte infiltration induced by leukotriene B 4 (Ϸ78% inhibition) or phorbol ester (Ϸ49% inhibition), which initiates endogenous chemokine production. These results indicate that this f luorinated analog of natural aspirin-triggered lipoxin A 4 is bioavailable by either local or systemic delivery routes and is a more potent and precise inhibitor of neutrophil accumulation than is ASA.
Aspirin (acetylsalicylic acid; ASA) has been available for use as an analgesic-antipyretic for almost a century (1) and novel therapeutic applications for this drug, for example in lowering the risk of myocardial infarction (2) or as a prophylaxis against colorectal cancer (3), continue to be uncovered. The acetylation of cyclooxygenases I and II (COX I and II) and the subsequent irreversible inhibition of prostaglandin and thromboxane biosyntheses are well understood mechanisms of some of ASA's pharmacological actions (4, 5) . More recently, ASA was found to cause a switch in eicosanoid biosynthesis as the acetylation of COX II changes the enzyme's activity to produce 15R-hydroxyeicosatetraenoic acid from agonist-released arachidonic acid (5) . Human neutrophils and other cells possessing 5-lipoxygenase use this substrate via transcellular biosynthetic routes to produce 15-epi-lipoxin A 4 (15-epi-LXA 4 ) and 15-epi-lipoxin B 4 (15-epi-LXB 4 ) (6, 7). These aspirin-triggered lipoxins (ATL) are the endogenous 15R enantiomeric counterparts of lipoxin A 4 (LXA 4 ) and lipoxin B 4 (LXB 4 ) respectively, and share their bioactivities (reviewed in ref. 6) .
Unlike other eicosanoids (e.g., leukotrienes, prostaglandins, etc.), which are generally considered local proinflammatory mediators, lipoxins (LX) display potent inhibitory actions in several key events in inflammation, such as polymorphonuclear cell (PMN) chemotaxis, transmigration across endothelial and epithelial cells, and diapedesis from postcapillary venules (6) . LX are generated in several pathogenic scenarios in vivo, for example: in lung tissue of patients with severe pulmonary disease (8) and by PMN from patients with asthma (9, 10) or rheumatoid arthritis (11) , where their presence is proposed to be linked to long-term clinical improvement. Interestingly, ATL show an even greater level of inhibition than native LX in preventing neutrophil adhesion, where they are approximately twice as potent (6) . ATL are also more potent inhibitors of microbial induction of cytokine release. Specifically, 15-epi-LXA 4 showed greater inhibition than LXA 4 of Salmonella typhimurium-induced secretion and gene regulation of the potent leukocyte chemoattractant IL-8, generated by intestinal epithelial cells (12) . It is therefore likely that, in addition to the inhibition of prostaglandin formation, the benefits of ASA therapy also result from the triggering of antiinflammatory lipid mediators that act locally to downregulate leukocytes.
PMN accumulation and activation play central roles in the pathogenesis of a wide range of disease states as diverse as rheumatoid arthritis (13) , atherosclerosis (14) , ulcerative colitis (15, 16) , and psoriasis (17) . Hence the elucidation of endogenous regulatory mechanisms that can control neutrophil functions is of considerable therapeutic interest. Because they are small lipophilic compounds amenable to total organic synthesis, the natural lipoxins, and specifically their endogenous isoform ATL, are well suited as potential leads for novel small molecule therapeutics as well as pharmacological tools for uncovering endogenous counter-regulatory and͞or antiinflammatory signaling pathways.
Design modifications that enhance biostability are advantageous because the lipoxins are autacoids that are rapidly biosynthesized in response to stimuli, in turn elicit counter-
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked ''advertisement'' in accordance with 18 U.S.C. §1734 solely to indicate this fact.
PNAS is available online at www.pnas.org.
Abbreviations: ASA, aspirin (acetylsalicylic acid); ATL, aspirintriggered lipoxins; ATLa1, 15(R͞S)-methyl-lipoxin A4; ATLa2, 15-epi-16-(para-fluoro)- phenoxy-lipoxin A4; COX I and II, cyclooxygenases  I and II; 15-epi-LXA4, 5S,6R,15R-trihydroxyeicosa-7E,9E,11Z,13E-tetraenoic acid; 15-epi-LXB4, 5S,6R,15R-trihydroxyeicosa-6E,8Z,10E,12E-tetraenoic acid; LC͞MS͞MS, liquid chromatography  tandem mass spectrometr y; LTB4, leukotriene B4, 5S,12 Rdihydroxyeicosa-6E,8Z,10Z,14E-tetraenoic acid; LX, lipoxins; LXA4,  lipoxin A4, 5S,6R,15S-trihydroxyeicosa-7E,9E,11Z,13E-tetraenoic  acid; LXB4, lipoxin B4, 5S,14R,15S-trihydroxyeicosa-6E,8Z,10E,12E-tetraenoic acid; PMA, phorbol 12-myristate 13-acetate; PMN, polymorphonuclear leukocyte; TNF-␣, tumor necrosis factor ␣; MS͞MS, product ion mass spectra. ‡ To whom reprint requests should be addressed. e-mail: cnserhan@ zeus.bwh.harvard.edu. regulatory responses, and then are rapidly enzymatically inactivated (6). 15-Hydroxy-prostaglandin dehydrogenase, which catalyzes the reversible oxidation of the carbon-15 position alcohol group of prostaglandins (18) , also catalyzes the first step of lipoxin inactivation (Fig. 1A Inset) (19, 20) . In view of these findings, several stable analogs of ATL and LXA 4 were designed that resist oxidation at carbon-15 by recombinant dehydrogenase in vitro (21) . Both LXA 4 and 15-epi-LXA 4 act at common LXA 4 receptors on leukocytes and are active within the nanomolar range, inhibiting PMN transmigration, diapedesis, and vascular permeability (21) (22) (23) . The stable LXA 4 and ATL analogs also compete at this LXA 4 receptor (23) . Here, we report that design modifications to native ATL biostabilize these mediators in whole blood to resist rapid inactivation. Moreover, the fluorinated ATL analog, namely 15-epi-16-(para-fluoro)-phenoxy-LXA 4 (ATLa 2 ), is a potent inhibitor of PMN recruitment in murine in vivo models when administered through both local and systemic routes.
MATERIALS AND METHODS
Biostability. The analogs 15(R͞S)-methyl-LXA 4 (ATLa 1 ) and ATLa 2 were prepared by total organic synthesis (21) and their structures confirmed by NMR. Male BALB͞c mice (6-to 8-wk old) (Harlan-Sprague-Dawley) were anesthetized with pentobarbital (70 mg͞kg), and whole blood was drawn via cardiac puncture into heparin (500 units͞ml). LXA 4 , ATLa 1 , and ATLa 2 (2.4 M) were incubated in 250 l of blood (37°C) for either 0 or 3 hr. For time zero (T ϭ 0), the blood aliquots were placed in an ice bath for 1 min and, immediately after the addition of LXA 4 or ATLa, were centrifuged at 800 ϫ g at 0°C for 20 min. The plasma supernatants were collected, stopped in 400 l of ice cold methanol, and stored at Ϫ20°C before solid phase extraction. For T ϭ 3 hr, the blood aliquots were incubated with ATLa and gently mixed by shaking at 37°C. After each incubation period, the plasma was collected and stopped as above. Prostaglandin B 2 (Oxford Biomedical Research, Oxford, MI) was added to the blood samples immediately before centrifugation as an internal standard for extraction recovery. Denatured protein precipitates were pelleted from the stopped plasma samples and were washed twice with 200 l of methanol. The plasma supernatant and washes were pooled and extracted with Extract-Clean solid phase extraction cartridges (500 mg C 18 , Alltech Associates). The methyl formate fractions were taken to dryness with a gentle stream of nitrogen and suspended in methanol for injection and quantitative analyses by UV spectrophotometry and liquid chromatography tandem mass spectrometry (LC͞MS͞MS).
LC͞MS͞MS Analyses. LC͞MS͞MS was performed using an LCQ (Finnigan-MAT, San Jose, CA) quadrupole ion trap mass spectrometer system equipped with an electrospray atmospheric pressure ionization probe. Samples were suspended in methanol and injected into the HPLC component, which consisted of a SpectraSYSTEM P4000 (Thermo Separation Products, San Jose, CA) quaternary gradient pump, a Prodigy octadecylsilane-3 (100 ϫ 2 mm, 5 m) column (Phenomenex, Belmont, CA) or a LUNA C18-2 (150 ϫ 2 mm, 5 m) column, and a rapid spectra scanning SpectraSYSTEM UV2000 (Thermo Separation Products) UV͞VIS absorbance detector. The column was eluted isocratically with methanol͞water͞ acetic acid (65:35:0.01, vol͞vol͞v) at 0.2 ml͞min into the electrospray probe. The spray voltage was set to 5-6 kV and the heated capillary to 250°C. LXA 4 and the ATLa were quantitated by selected ion monitoring for analyte molecular anions (e.g., [M-H] Ϫ ϭ m͞z 351.5 for LXA 4 , m͞z 365.5 for ATLa 1 , and m͞z 405.5 for ATLa 2 free acid) or by UV absorbance at 300 nm. Product ion mass spectra (MS͞MS) were also acquired for definitive identification of the compounds.
PMN Infiltration into Mouse Air Pouch.
While male BALB͞c mice (6-8 wk) were anesthetized with isoflurane, dorsal air pouches were raised by injecting 3 ml of sterile air subcutaneously on days 0 and 3 (as in ref. 24 ). On day 6 and while the mice were anesthetized with isoflurane, 10 g of ATLa 2 was delivered as a bolus injection either into the tail vein in 100 l of sterile 0.9% saline or locally into the air pouch in 900 l of PBS Ϫ͞Ϫ (Dulbecco's Phosphate Buffered Saline without magnesium or calcium ions, BioWhittaker). Dexamethasone and ASA (Sigma) were delivered locally as 10 g and 1.0 mg doses in 900 l of PBS Ϫ͞Ϫ, respectively. Inflammation in the air pouch was induced by local injection of recombinant murine tumor necrosis factor ␣ (TNF-␣) (20 ng) (Boehringer Mannheim) dissolved in 100 l of sterile PBS. While the mice were anesthetized with isoflurane, the air pouches were lavaged twice with 3 ml of sterile PBS 4 hr after the initial TNF-␣ injection. Aspirates were centrifuged at 2,000 rpm for 15 min at 23°C. The supernatants were removed, and the cells were suspended in 500 l of PBS. Aliquots of the cell suspension were stained with Trypan blue and enumerated by light microscopy. Resuspended aspirate cells (50 l) were added to 150 l of 30% BSA and centrifuged onto microscope slides at 2,200 rpm for 4 min by using a Cytofuge (Statspin, Norwood, MA). Slides were allowed to air dry and were stained with Wright Giemsa stain (Sigma) for determination of differential leukocyte counts. For microscopic analysis, tissues were obtained with a 6-mm tissue biopsy punch (Acu-Punch, Acuderm, Ft. Lauderdale, FL) and fixed in 10% buffered formaldehyde. Samples were then embedded in paraffin, sliced and stained with hematoxylin-eosin.
Arterial Pressure. Male BALB͞c mice (6-to 8-wk old, 20 g) were anesthetized with pentobarbital (80 mg͞kg). The trachea was isolated and a small polyethylene catheter (PE50) was introduced to maintain a patent airway. The right carotid artery was isolated and cannulated with PE10 tubing filled with heparinized (10 units͞ml) normal saline. The arterial catheter was connected to a pressure transducer (World Precision Instruments, Sarasota, FL), and the arterial pressure tracing was recorded continuously (Astromed MT95K2, West Warwick, RI). All surgical manipulations were performed by using a surgical microscope (Zeiss).
PMN Infiltration into Ear Skin. The mouse ear inflammation model (22) was used to evaluate the impacts of i.v. and topical deliveries of ATLa 2 on leukotriene B 4 (LTB 4 )-and phorbol 12-myristate 13-acetate (PMA)-induced PMN infiltration. Briefly, ATLa 2 either was applied topically (20 g in 10 l acetone) to the inner side of the left mouse ear with vehicle applied contralaterally or was delivered as a bolus injection (10 g in 100 l of 0.9% sterile saline) through the tail vein. Five to seven minutes later, inflammation was induced in left and right ears of the mice that received topical ATLa 2 (left ear only in the mice receiving i.v. delivery of ATLa 2 ) by topical application of either LTB 4 (1 g) or PMA (100 ng) in acetone (10 l). After 24 hr, 6-mm-diameter tissue punch biopsies were taken (Acu-Punch) from the ears and assayed by the method of Bradley et al. (25) for myeloperoxidase activity as an index of PMN number. Isolated murine PMNs were enumerated by light microscopy and processed in the same manner to obtain a calibration curve.
Plasma Clearance. The time course for the clearance of ATLa 2 from plasma after tail vein injection was determined over 50 min. Male BALB͞c mice (6-to 8-wk old, 20 g) were anesthetized with pentobarbital (70 mg͞kg) and received bolus tail vein injections of 27 M ATLa 2 (0.1 mg͞kg) in 100 l of sterile 0.9% saline. Blood was taken from the mice by cardiac puncture at 2, 5, 10, 15, and 50 min postinjection. The plasma was obtained and extracted as above, with the methyl formate fractions from the solid phase extraction dried down for LC͞MS͞MS analysis. Values for ATLa 2 quantified in plasma (1999) are expressed in units of ng͞ml plasma taken from the mouse, with n ϭ 3 for each time point.
RESULTS
Biostability. After 3-hr incubations of LXA 4 in mouse whole blood ex vivo, the predominant metabolite peak observed in the LC͞MS chromatogram of the extracted sample had a retention time and MS͞MS spectrum matching that of 15-oxo-LXA 4 , as generated by recombinant 15-hydroxy-prostaglandin dehydrogenase from synthetic LXA 4 (Fig. 1 A) . To determine whether addition of bulky substituents to the native LX structure enhances biostability, two aspirin-triggered lipoxin stable analogs, ATLa 1 and ATLa 2 , were incubated in mouse whole blood and compared with LXA 4 . A methyl group at carbon-15 was placed as a racemate to protect both LXA 4 and 15-epi-LXA 4 in ATLa 1 , and a fluoride was placed at the para position of the phenoxy ring of 15-epi-16-phenoxy-LXA 4 in ATLa 2 (Fig. 1B) . LC͞MS͞MS analysis of whole blood incubations showed that Ϸ40% of LXA 4 was lost, whereas both ATLa 1 and ATLa 2 exhibited greater stability with Ϸ90% and Ϸ100% remaining, respectively (Fig. 1B) . In human whole blood, quantitatively similar results were obtained with ATLa 1 (data not shown). Because ATLa 1 and ATLa 2 appear to give essentially equivalent activity, to spare animals we performed in vivo experiments with ATLa 2 .
Intravenous and Local Delivery of ATLa 2 Inhibits TNF-␣-Induced PMN Infiltration in the Dorsal Air Pouch. The 6-day murine dorsal air pouch is characterized by the presence of a nascent lining that encloses the air cavity and is composed of both fibroblast-like cells, which are indistinguishable from type B cells of murine knee synovium, and macrophage-like cells, which share morphology with synovial type A cells (26) . The air pouch therefore serves as an in vivo model of the rheumatoid synovium (24, 26) and was used here to evaluate the impact of intravenous and local delivery of ATLa 2 in the inhibition of cytokine-mediated inflammation and for direct comparison to the actions of ASA and dexamethasone. TNF-␣ induces leukocyte infiltration, predominantly neutrophils (Ͼ75%), into the pouch with maximal cell accumulation occurring between 2-4 hr postinjection (27) . ATLa 2 , dexamethasone, and ASA were each injected locally into the air pouch of individual mice and immediately before the administration of murine TNF-␣. For systemic delivery of ATLa 2 , injections were given via the mouse tail vein before local air pouch injection of murine TNF-␣. Here, local delivery of TNF-␣ alone (20 ng͞mouse) induced the recruitment of 4.8 Ϯ 1.1 ϫ 10 6 PMN into the air pouch at 4 hr (Fig. 2) . When ATLa 2 was delivered locally into the air pouch (10 g͞mouse), only 1.1 Ϯ 0.3 ϫ 10 6 PMN were present in the pouch exudate, representing Ϸ77% inhibition of the TNF-␣-induced PMN infiltration. Delivery of ATLa 2 (10 g͞mouse) by i.v. injection proved to be an even more potent method of inhibiting TNF-␣-driven PMN infiltration. The PMN recruitment values dropped to an average of 7.9 Ϯ 2.9 ϫ 10 5 PMN͞air pouch, representing an inhibition of Ϸ85%. Moreover, no apparent PMN), whereas a 100-fold greater dose of ASA (1.0 mg͞mouse) was required to inhibit PMN infiltration to a similar degree as ATLa 2 . The presence of 1.5 Ϯ 0.6 ϫ 10 6 cells with 1.0 mg ASA represents 69% inhibition compared with TNF-␣ administration alone given to mice in parallel. The mean values of PMN in the air pouch exudates indicate a trend toward increased potency with local or i.v. delivery of ATLa 2 compared with dexamethasone. The mean number of PMN after i.v. ATLa 2 treatment was significantly different from that after local administration of dexamethasone at 90% confidence (P ϭ 0.085; Student's two-tailed t test), but not within the 95% confidence interval (P Ͼ 0.05).
Histological analysis of the tissue lining surrounding the air pouch cavity showed that the addition of TNF-␣ resulted in a markedly increased number of neutrophils (Fig. 3A) , which was reduced when ATLa 2 was delivered either by intrapouch injection (Fig. 3B) or i.v. via the tail vein (Fig. 3C ) before TNF-␣ administration. Moreover, microscopic analyses of dermal tissue from mice that received ATLa 2 treatment were indistinguishable from those exposed only to vehicle (Fig. 3D) , which also showed a mild neutrophil infiltrate accompanying this wound model. ATLa 2 Does Not Inhibit PMN Recruitment by Regulating Vasoactivity. LXA 4 exhibits both concentration-and vascular bed-dependent vasoactive properties. For example, topical administration of LXA 4 (1 M) induces arteriolar dilation in the hamster cheek pouch with no change in venular diameters, whereas systemic delivery into rats produces a vasoconstrictor response in the mesenteric bed (28) . In addition, 20 min infusion of 1 or 2 g͞kg LXA 4 induces renal vasorelaxation in rats without changing mean arterial pressure (29) . To determine whether the increased stability of ATLa 2 enhances potential vasoreactivity at the therapeutic dose found to inhibit PMN infiltration in Figs. 2 and 5, vascular changes in response to ATLa 2 were compared directly to those of Iloprost, a prostacyclin stable analog that rapidly stimulates arterial vasodilation (30) . Added to organ baths, ATLa 2 relaxed precontracted isolated rat aorta to Ϸ40% of the level of relaxation caused by equimolar treatment (1 M) with Iloprost (results are available as supplemental material on the PNAS web site, www.pnas.org). However, when 10 g, or Ϸ24 nmol͞mouse, of ATLa 2 was injected into the tail vein as in Fig. 2 , no apparent changes in mean arterial pressure were observed (Fig. 4) . In sharp contrast, injection of equimolar quantities of Iloprost elicited a maximum mean decrease of Ϸ28 mmHg (1 Hg ϭ 133 Pa) Ϸ50 s postinjection, with pressure returning to baseline after Ϸ8 min.
ATLa 2 Inhibits PMN Infiltration in Murine Ear Skin to Both Exogenous and Endogenous Chemoattractants.
Topical application of ATLa 1 , a carbon-15 racemic analog with properties of both 15-epi-LXA 4 and native LXA 4 , and 16-phenoxy-LXA 4 (an analog of LXA 4 ) to mouse ear epidermis inhibits LTB 4 -induced PMN influx as well as vascular permeability changes (22) . Here, this ear skin model of inflammation was used to determine whether i.v. or topical delivery of the whole blood stable ATLa 2 could also inhibit PMN influx, which is maximal at 24 hr after topical application of either LTB 4 or PMA to skin. Topical application of ATLa 2 inhibited both LTB 4 -and PMA-induced inflammation, by Ϸ78% and Ϸ49% respectively (Fig. 5) . In contrast to i.v. and dorsal administration in the air pouch, a single bolus i. g) did not inhibit PMN influx at 24 hr with either agonist applied topically to ear skin (Fig. 5) . But, when a second i.v. injection of this analog was repeated at 20 hr (4 hr before PMN determinations), LTB 4 -induced PMN recruitment was inhibited by Ϸ22% (not shown). ATLa 2 Is Rapidly Cleared from Plasma After I. V. Injection. Because i.v. tail vein delivery of ATLa 2 elicited a potent antiinflammatory response blocking PMN infiltration within a 4-hr period in the dorsal air pouch (Fig. 2) but not at 24 hr in the ear skin (Fig. 5) , the question arose as to what extent ATLa 2 possessed enhanced biostability in circulation after bolus tail vein injections. To address this question, ATLa 2 was extracted from mouse plasma collected at several time intervals after tail vein injections, and the recovered materials were quantitated by LC͞MS͞MS. At 2 min postinjection, Ϸ34 ng͞ml plasma was detected. The levels of the analog decreased with time and were not detected after 15 min. These results indicate rapid clearance from blood and therefore rapid distribution and͞or elimination (Fig. 6 ).
DISCUSSION
We report here that a fluorinated analog of 15-epi-LXA 4 , ATLa 2 , is a stable analog inhibitor of both direct-(LTB 4 ) and indirect-(TNF-␣, PMA) acting chemoattractants. These in vivo observations further support the role of the aspirintriggered lipoxin circuit as an additional mechanism underlying aspirin's antiinflammatory therapeutic impact and provide evidence for endogenous antiinflammatory signaling pathways.
Our results indicate that specific design modifications of the native LXA 4 structure, such as the addition of a C-15 methyl group (ATLa 1 ) or a bulky -chain (para-fluoro)-phenoxy group (ATLa 2 ), prolong the lifetime in blood of these compounds and therefore, potentially, their bioavailabilities as well. Such modifications sterically hinder conversion of the analogs, relative to rapid bioinactivation of the native structure, by recombinant 15-hydroxy-prostaglandin dehydrogenase in vitro (6) . As evidenced by LC͞MS͞MS analyses, the major product of this human dehydrogenase incubated with LXA 4 is 15-oxo-LXA 4 . LC͞MS͞MS analyses showed that 15-oxo-LXA 4 also was produced from LXA 4 in mouse whole blood (Fig. 1 A) , suggesting that the mouse shares with the human a common pathway for LXA 4 inactivation.
ATLa 2 proved to be a potent inhibitor of TNF-␣-induced PMN infiltration into the air pouch cavity, as doses as low as 24 nmol per mouse delivered locally into the air pouch or by systemic i.v. injection via the tail vein resulted in Ϸ77% and Ϸ85% inhibition, respectively. Histologically, this wound model is thought to resemble rheumatoid synovium (26) , and TNF-␣ injection initiates PMN recruitment to the cavity (Fig.  2) . Injection of TNF-␣ into the air pouch increases, within the surrounding tissue, C-C chemokine (murine monocyte chemotactic peptide-1 and macrophage inflammatory protein-1␣) and C-X-C chemokine (macrophage inflammatory protein-2) production and increases messenger RNA levels for the aforementioned chemokines as well as murine growth-related oncogene protein-␣, all of which are collectively required for neutrophil recruitment (27) . Because ATLa 2 blocked TNF-␣-induced PMN infiltration (Fig. 2) , ATL disrupts this chemokine network in vivo. This finding may have therapeutic implications, as a variety of pathological conditions, including rheumatoid arthritis, psoriasis, and Crohn's disease, have associated with them an overproduction of TNF-␣ and therefore control of this cytokine's actions is highly sought (31) .
We also found that ATLa 2 was more potent than ASA because a 100-fold greater dose of ASA, delivered locally to the air pouch, resulted in a level of inhibition of TNF-␣-driven PMN recruitment that was less than that of ATLa 2 . Furthermore, local administration of an equivalent dose of dexamethasone inhibited PMN infiltration at a lower mean value than inhibition by ATLa 2 (Fig. 2) . Given the unwanted side effects associated with the structures of both ASA (acidity that can lead to ulceration) and dexamethasone (steroid structure that can also impact physiologic steroidal functions), structurally distinct compounds such as ATL analogs designed on the basis of endogenous regulators of leukocyte function may prove to be advantageous therapeutic alternatives.
Applied topically to the ear, ATLa 2 also inhibited both LTB 4 -and PMA-induced PMN recruitment by Ϸ78% and Ϸ49%, respectively (Fig. 5) . LXA 4 and ATLa 1 exhibit similar IC 50 s in vitro in the inhibition of PMN transmigration across polarized epithelial monolayers or PMN adherence to vascular endothelial cells (21) . Topical delivery of ATLa 1 inhibits LTB 4 -induced PMN recruitment, but interestingly the level of inhibition afforded by the native LXA 4 applied topically was less than 25% compared with that of either ATLa 1 or ATLa 2 (22) . These observations regarding in vitro vs. in vivo potencies between the analogs and the native structure indicate that the ATL analogs possess enhanced bioavailability in vivo. Thus, in addition to protection from enzymatic inactivation, the structural modifications to the native LXA 4 structure incorporated in ATLa 1 and ATLa 2 also improved their topical delivery and contributed to rapid distribution to tissue (Fig. 2) .
Results obtained from the air pouch model 4 hr after administration of the analog indicate that i.v. delivery of ATLa 2 to a remote site of inflammation was surprisingly even more effective than topical application. In sharp contrast are the findings with ear skin, where topical application of ATLa 2 elicited substantial inhibition of topically applied proinflammatory mediators; i.v. delivery of the analog showed no apparent inhibition of LTB 4 -induced PMN recruitment. We also found that the ATL analog was stable ex vivo in whole blood suspensions, with essentially complete quantitative recovery at 3 hr, and was rapidly cleared from plasma after i.v. injection into the tail vein (between 15 and 50 min). Taken together, these results suggest that ATLa 2 is rapidly distributed to tissues from i.v. injections, rather than eliminated, and could remain in an active form for several hours, e.g., during the time course of the TNF-␣-driven PMN recruitment to the wounded dorsal pouch (Fig. 2) . Furthermore, the absence of PMN inhibition through systemic delivery in the mouse ear model suggests that ATLa 2 displays site-selective bioaction from circulation, such as to the dorsal pouch rather than to ear skin. An alternate explanation for the differences in efficacy in ear skin vs. the air pouch after i.v. administration may result from differential distribution within the tissues. Hence, after injection of ATLa 2 , a rapid distribution to the air pouch might serve as a reservoir permitting the compound's potent bioactivity in this tissue. Along these lines, ear skin may lack such storage of ATLa 2 and thus, coupled with rapid plasma clearance, systemic impact is muted at 24 hr within ear skin.
In summary, these results indicate that the inhibitory actions of aspirin-triggered lipoxins are both tissue-and delivery site-dependent and are the first to show that stable analogs of ATL inhibit acute inflammation at sites distant from the point of delivery. Because ATL stable analogs were designed as mimetics to incorporate the native aspirin-triggered structural features, the present findings, taken together, provide new tools to examine endogenous antiinflammatory pathways as well as avenues to approach the development of both topical and intravenous anti-PMN therapies.
